NCT03989089: Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation

NCT03989089
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: APOBEC3B
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have germline APOBEC3B mutation; Patients must have received at least 1 but not more than 3 prior lines of palliative chemotherapy for metastatic breast cancer; ER+ patients must have received at least 1 line of hormonal therapy in the metastatic setting
Exclusions: Patients with known, active, untreated, or unstable CNS metastases and/or carcinomatous meningitis- see trial for details; Patients with prior immunotherapy of an anti-PD-1, anti-PD-L1/2, or CTLA-4
https://ClinicalTrials.gov/show/NCT03989089

Comments are closed.

Up ↑